Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Regulatory Update For Qnexa Could Signal A Change In The Obesity Landscape

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

New developments for Vivus’ weight loss drug Qnexa may mean that the regulatory environment for obesity treatments could be improving.

You may also be interested in...

Arena Ready For FDA To Reconsider Weight-Loss Drug Lorcaserin

Arena and Eisai expect to hear in the next week or so whether FDA will accept their answer to an October 2010 “complete response” letter and set a new action date for their novel weight loss drug.

Qnexa’s Second Advisory Committee Review: Smaller Indication, Still Big Safety Questions

Vivus’ weight loss drug Qnexa (phentermine/topiramate) will go before the Endocrinologic and Metabolic Drugs Advisory Committee again on Feb. 22 for an indication that excludes women of childbearing age. And despite additional safety data, cardiovascular concerns look to remain a major issue for the resubmitted application.

Orexigen Resurrects Contrave With New Trial Agreement With FDA

The biotech breathes new life into its obesity program now that it has reached agreement with FDA on a two-year cardiovascular safety study for Contrave.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts